The Use of a Stably Expressed FRET Biosensor for Determining the Potency of Cancer Drugs

• William P. Bozza,

  Affiliation Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Xu Di,

  Affiliation Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Kazuyo Takeda,

  Affiliation Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Leslie A. Rivera Rosado,

  Affiliation Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Sarah Pariser,

  Affiliations Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America, Brown University, Providence, Rode Island, United States of America

  ⨯
• Baolin Zhang

  * E-mail: Baolin.zhang@fda.hhs.gov

  Affiliation Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯